Kornimate/medical-research-clean huggingface dataset:
the correlation between sevoflurane and qnox

Conditions: Analgesic Adverse Reaction; Nociceptive Pain; Inhalation; Vapor

Summary: this study purpose to observation the sevoflurane analgesia effect, and using nociception real-time monitoring nox to test the correlation between the sevoflurane and nox index.

this study purpose to observation the sevoflurane analgesia effect, and using nociception real-time monitoring nox to test the analgesia effect of the sevoflurane. and test the correlation between the sevoflurane and nox index.

Eligibility criteria:
inclusion criteria: 1. elective thoracoscope surgery patients 2. age ranging from 25 to 85 years 3. american society of anesthesiologists (asa) physical status score of 2 to 4 4. a body mass index (bmi) ranging from 18.5 to 40 kg/m2. exclusion criteria: 1. clinical diagnosis of alzheimer's disease 2. implanted pacemaker 3. clinical diagnosis of psychiatric diseases 4. clinical diagnosis of epilepsy 5. clinical diagnosis of autonomic nervous system disorders which might affect the eeg
study evaluating ldl-c change and adherence to inclisiran lipid-lowering therapy in ascvd

Conditions: Primary Hypercholesterolemia; Mixed Dyslipidemia

Summary: this observational prospective study aims to evaluate the ldl-c change and adherence to inclisiran in combination with other llts under conditions of routine clinical practice.

patients will be enrolled over a period of \~31.5 months, and followed for up to 24 months to assess for study outcomes.

Eligibility criteria:
inclusion criteria: 1. participants who are 18 years or older 2. participants with hypercholesterolemia having a diagnosis of ascvd, ascvd re or hefh 3. participants who are not at ldl-c goal as per their cv risk according to respective clinical guidelines 4. participants who per physician's criteria need to optimize their llt 5. participants who provide written informed consent to participate in the study 6. participants who initiate inclisiran under conditions per local label and have ldl-c values available at baseline or within 3 months before treatment initiation. exclusion criteria: 1. participants that have received inclisiran previously 2. participants participating in a clinical trial with investigational product 3 participants switching from previous pcsk9 mab treatment (within 90 days prior to index date

Keywords: primary hypercholesterolemia mixed dyslipidemia real-world study inclisiran lipid-lowering therapy llt ascvd
rehabilitation and recovery for persons with esophageal or gastric cancer

Conditions: Esophageal Cancer; Esophageal Neoplasms; Gastric Cancer; Stomach Neoplasm

Summary: this study aims to develop and evaluate a model for systematic and evidence-based cancer rehabilitation for people with esophageal and gastric cancer to provide conditions for a better quality of life and fewer cancer-related symptoms.

sweden has had a national cancer rehabilitation programme since 2014. this emphasises that all people with cancer have the right to individualised rehabilitation and that the contact nurse has an important role to play in identifying needs and ensuring evidence-based interventions throughout the cancer process to promote rehabilitation. the needs for optimised rehabilitation vary according to several parameters such as the person's personal circumstances and preferences, social support and type of cancer disease. despite this and a growing number evidence within this area cancer rehabilitation is often not integrated in clinical care. the current cancer care focuses on medical and treatment related interventions. it is a challenge for health services to find models to identify and meet the increased need for cancer rehabilitation in a systematic and structured way throughout the cancer process, based on the specific needs of each individual. this study aims to develop and evaluate a model for systematic and evidence-based cancer rehabilitation for people with esophageal and gastric cancer to provide conditions for a better quality of life and fewer cancer-related symptoms.

Eligibility criteria:
inclusion criteria: * over 18 years of age * esophageal or gastric cancer * living in southern sweden (skåne) * are planned to undergo curative surgerytreatment at skåne university hospital. exclusion criteria: * unable to communicate in the swedish language * suffering from a cognitive impairment that poses a barrier for participating in the study.

Keywords: cancer rehabilitation recovery
research on optimal diagnosis and treatment of cardiorenal syndrome

Conditions: Heart Failure; Kidney Diseases; Kidney Injury; Heart Valve Diseases; Dialysis; Complications; Coronary Heart Disease

Summary: to estimate the characteristics, pathogenesis, risk factors and intervention measures for different stages of heart and kidney diseases, and to optimize the curative effects of different treatment schemes

cardiorenal syndrome is a clinical syndrome caused by acute or chronic injury of one of the heart and kidney resulting to acute or chronic dysfunction of the other organ. in recent years, the morbidity of cardiorenal syndrome has increased rapidly in china. its condition is complex and difficult to treat. due to the lack of studies specifically targeting the cardiorenal syndrome population, there is no systematic in-depth understanding of the pathogenesis and risk factors of this kind of disease. in clinic, the course of various types of cardiorenal syndrome is complex and difficult to be summarized into a specific type. therefore, we intend to conduct a clinical systematic observation and research on such patients so as to optimize a more reasonable treatment scheme.

Eligibility criteria:
inclusion criteria: patients meet the diagnosis of various types of cardiorenal syndrome according to the classification standards of various types formulated by kdigo and adqi expert consensus. different syndromes were identified and classified into five subtypes. acute crs (type 1): acute worsening of heart function (ahf-acs) leading to kidney injury and/or dysfunction. chronic cardio-renal syndrome (type 2): chronic abnormalities in heart function (chf-chd) leading to kidney injury and/or dysfunction. acute reno-cardiac syndrome (type 3): acute worsening of kidney function (aki) leading to heart injury and/or dysfunction. chronic reno-cardiac syndrome (type 4): chronic kidney disease leading to heart injury, disease, and/or dysfunction. secondary crs (type 5): systemic conditions leading to simultaneous injury and/or dysfunction of heart and kidney. exclusion criteria: pregnant or breastfeeding women; female patients with recent birth plans; patients who cannot follow up on medications.
safety study of entocort for children with crohn's disease

Conditions: Crohn's Disease

Summary: a safety study using entocort ec for children with mild to moderate crohn's disease

a multicenter, open label, non-comparative study to evaluate the safety of entocort ec for the treatment of crohn's disease in paediatric subjects aged 5 to 17 years, inclusive

Eligibility criteria:
inclusion criteria: * all male and female subjects must be aged 5 to 17, inclusive, and must not have reached their 18th birthday by the estimated final office visit. * subject must be diagnosed with active crohn's disease of the ileum and/or ascending colon confirmed by endoscopic and/or radiographic evidence, and/or evidence of mucosal erosions and/or histology. * subjects with mild to moderate crohn's disease. * all subjects must have a stool analysis negative for clostridium difficile toxin, yersinia enterolytica, campylobacter jejuni, salmonella, shigella, within the 30 days prior to visit 1. * all subjects must have had laboratory assessments within 7 days prior to visit 1. * all subjects must weigh \>= 15 kg at time of enrollment exclusion criteria: * subjects who have had any previous intestinal resection proximal to and including the ascending colon * subjects with evidence of severe active crohn's disease and/or, stricturing and prestenotic dilatation, clinical evidence of obstruction, perirectal abscess, perirectal disease with active draining fistulas, perforation, or any septic complications * subjects who do not have a negative stool analysis, within the 30 days prior to visit 1 * subjects who have been screened/or enrolled in this study previously within the last 30 days * subjects with morning cortisol level \<150 nmol/l (5.4 ug/dl) or dhea-s below normal range for age and gender
invasive pulmonary aspergillosis complicating influenza infection

Conditions: Influenza With Pneumonia; Aspergillosis Invasive

Summary: study the incidence and outcome of invasive pulmonary aspergillosis (ipa) in icu patients with severe influenza and in influenza-negative control patients with severe community-acquired pneumonia

this prospective multicentre case-control registration study in dutch and belgian icus will assess the difference in incidence and outcome of invasive pulmonary aspergillosis (ipa) in icu patients with severe influenza compared with influenza-negative control patients with severe community-acquired pneumonia during the coming three influenza seasons (2017-2020). the study will further assess the differences in clinical characteristics and risk factors between influenza patients with and without invasive aspergillosis. all consecutive patients aged 18 or older admitted to icu during the inclusion period with respiratory distress due to influenza positive/negative community acquired pneumonia (cap) will be included.

Eligibility criteria:
inclusion criteria: * patient older than 18 years,admitted to icu with respiratory distress with microbiologically confirmed diagnosis of influenza (for inclusion in the influenza group) * patients older than 18 years, admitted to icu for respiratory distress due to community-acquired pneumonia , with a microbiologically confirmed absence of influenza (for inclusion in the control group) exclusion criteria: * age \< 18 year * no informed consent

Keywords: icu
elevate - (empower lupus erythematosus patients via allowing remote evaluation)

Conditions: Systemic Lupus Erythematosus

Summary: to explore the potential for use of dxterity's aip ifn-1 test as personalized guided care and monitoring module in patients with systemic lupus erythematosus(sle) using consented patient health information

explore and demonstrate concordance between self-collected samples and traditional phlebotomist venous draw for dxterity aip module and biomarkers like c3, c4, anti dsdna and crp in sle participants with self-reported outcomes and medical record data. the study will collect blood samples and self-reported information for sle subjects, up to 5000 participants in phase i, with a subset of 1000 continuing to phase ii with medical records. study participants will be recruited using a combination of digital media (including social media, advertising, bloggers, emails). enrollment and qualification will be done along with consented retrieval of medical records using a study specific mobile app.

Eligibility criteria:
inclusion criteria: (phase i) 1. individuals aged 18 years or older. 2. must reside in united states 3. have a clinical diagnosis of sle 4. willingness to consent to provide electronic medical records (emr) 5. provide written informed consent and comply with the study procedures. (phase ii) 1. verified diagnosis (medical records or /and physician questionnaire) for sle 2. report one or more of the following (record all that apply): 1. worsening or changes in symptoms or flare 2. changes in treatment regimen 3. on standard of care treatment 4. on biologics exclusion criteria: 1. participants unable to complete study requirements
use of cest (chemical exchange saturation transfer) imaging in pet/mri

Conditions: Glioma; Brain Metastases

Summary: standard magnetic resonance imaging (mri) is based on the excitation of hydrogen nuclei that are presents in water molecules, which abundance in human body allows for obtention of superior contrast. however, assessing the presence of other molecules than water in tissues is also of great clinical interest to probe metabolites related to physiological body function and pathological conditions. chemical exchange saturation transfer (cest) allow to overcome some limitations of proton magnetic resonance spectroscopy (1h-mrs) by exploiting chemical properties of the targeted molecule through a continuous process of re-saturation and exchange, and thus detecting it with increased sensitivity, from two orders of magnitude. moreover, cest technique is based on imaging sequences and can therefore benefit from well-known fast acquisition strategies, as well as improved spatial resolution.

for this study the investigators propose to include an additional cest sequence in standard pet/mri exam in order to obtain a cartography with biochemical informations from tissues in patients with glioma or brain metastases.

Eligibility criteria:
inclusion criteria: patients admitted to the nuclear medicine and molecular imaging department of icans (institut de cancérologie strasbourg europe) for a pet/mri exam dedicated to: * preoperative evaluation of a cerebral expansion lesion * evaluation of glioma recurrences * evaluation of brain metastases * evaluation of recurrence of metastases exclusion criteria: * contraindication to the realization of an mri * minor or patients placed under guardianship or supervision * patients deprived of liberty * patients placed under judicial protection * patients that are not able to express their consent * pregnant and breastfeeding women
safety and efficacy trial of rpc1063 for moderate to severe ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to determine whether rpc1063 is effective in the treatment of ulcerative colitis (uc).

the trial is composed of 2 periods: induction and maintenance. in the induction period (ip), patients will be entered into the trial in 2 separate cohorts (cohort 1 and cohort 2).patients from cohort 1 and 2 in clinical response at the end of the ip will proceed through to the maintenance period (mp). patients from cohort 1 and 2 who participate in this trial may also qualify to participate in an optional open-label extension (ole) trial.

Eligibility criteria:
inclusion criteria: * aged 18 to 75 years (at screening for cohort 1 and 2) * uc confirmed on endoscopy * moderately to severely active uc (may score 6-12) * currently receiving treatment with aminosalisylate, prednisone, or budesonide * can be receiving azathioprine, mercaptopurine, or methotrexate, but treatment will be stopped prior to randomization exclusion criteria: * have severe extensive colitis as evidence by: * physician judgment that the patient is likely to require colectomy or ileostomy within 12 weeks of baseline. * current or recent (within 3 months) evidence of fulminant colitis, toxic megacolon, or bowel perforation. * diagnosis of cd, indeterminate colitis, or the presence of fistula consistent with cd or microscopic colitis, radiation colitis, or ischemic colitis * clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk * history of uveitis or unknown macular edema * pregnancy, lactation, or a positive serum β-human chorionic gonadotropin (β-hcg) measured during screening
safety, feasibility, and tolerability of sulforaphane in children with chronic kidney disease

Conditions: Pediatric Kidney Disease

Summary: this purpose of this study is to investigate potential new therapeutics in pediatric chronic kidney disease (ckd). the specific aims are to identify safe dosing and tolerability of sulforaphane (sfn) supplementation in children with moderate and advanced ckd. secondary objectives will include preliminary exploration of changes in oxidative and inflammatory biomarkers in response to sfn supplementation in this population.


Eligibility criteria:
inclusion criteria: * diagnosis of chronic of kidney disease * have egfr 20-59 ml/min/1.73m2 at the time of enrollment * parents must be able to provide consent exclusion criteria: * weight \<30 kg * cancer or hiv diagnosis * history of solid organ transplantation (including kidney transplant) * structural heart disease * currently pregnant or plan to become pregnant * life expectancy is less than one year * patients will also be excluded if they are currently taking anticoagulants, immunosuppression, or chemotherapeutics
traumeel s for reduction of post operative pain following arthroscopy

Conditions: Post-operative Pain

Summary: the perception of pain is a complex process that is not yet fully understood. with outpatient knee arthroscopy becoming standard of care, postoperative pain management has become increasingly important in caring for patients. traumeel s is a homeopathic complex widely used in german-speaking europe for orthopedic pain and inflammation. it contains a mixture of medicinal plants and minerals, all highly diluted. in some recent studies, traumeel has shown anti-inflammatory and analgesic activity. in this study, the efficacy of traumeel s will be compared with placebo in reducing pain during the first 48 hours after arthroscopy. also compared will be 6 day pain levels, analgesic consumption, quality of life, post operative knee function, quadriceps atrophy and safety. the study design is double blind rct. 98 patients, aged 18-40 and undergoing arthroscopic meniscectomy or chondroplasty will be enrolled in the trial. patients will be randomized to receive either intraoperative join irrigation with traumeel s and oral treatment with traumeel s, or placebo irrigation and oral ingestion. patients will continue to take active or placebo medication for 6 days. pain will be recorded daily by the patient in the patient diary using an 11-point numerical rating score (nrs-11. patients will also record daily consumption of primary and "rescue" analgesics. range of motion (rom) will be measured on days 6 and 30 post-operatively, and the lysholm knee scale and circumference of thigh above patella will be measured at 30 days. all these measures will be compared with baseline. patients will be contacted daily by the research assistant to encourage compliance and to record their daily nrs and analgesic consumption in the crf.


Eligibility criteria:
inclusion criteria: * patients of either sex undergoing unilateral arthroscopy for menisectomy or chondroplasty, w/o ligament reconstruction . * age 18 - 40 years. * meeting none of exclusion criteria. exclusion criteria: * participation in another clinical trial within 4 weeks prior to enrollment. * inability to comply with the study protocol. * impossibility to be reached during the whole follow-up period (7 days post operative) * refused to give oral consent to the telephone interviews * previous arthroscopy on ipsilateral knee. * current use of analgesia for any other reason except for the knee complaint. * any disease considered to inhibit wound healing (e.g. diabetes mellitus, berger, any pvd, dvt). * known sensitivity to dipyrone or diclofenac

Keywords: homeopathy traumeel s arthroscopy pain management post-operative pain following arthroscopy
a study of maribavir in adults with post-transplant cytomegalovirus (cmv) infection in belgium

Conditions: Cytomegalovirus (CMV)

Summary: cytomegalovirus (cmv) is a common virus that infects many people. it can cause serious illness in people with weak immune systems especially in those undergoing transplants. maribavir is a medicine approved for treating cmv infection in adults after transplant. the main aim of this study is to check the use of maribavir and learn how safe and effective in treating adults with cmv infection after transplant in belgium in line with the belgian reimbursement criteria. during the study, a participant's data will be collected for 2 years. the study does not have fixed visits to the hospital, but it is recommended collect data from routine visits and contacts.


Eligibility criteria:
inclusion criteria: * participant signed an informed consent form. * aged greater than or equal to (\>=) 18 years at the time of consent. * received an hsct/sot. * diagnosed with cmv infection/disease any time after the hsct/sot date. * starting maribavir for the first time and in line with the belgian reimbursement criteria. exclusion criteria: • participant treated with maribavir before the start of the study.

Keywords: drug therapy
a study to evaluate the long-term safety, tolerability and efficacy of bimekizumab in adult patients with chronic plaque psoriasis

Conditions: Chronic Plaque Psoriasis

Summary: this is a study to assess the long-term safety, tolerability, and efficacy of bimekizumab.


Eligibility criteria:
inclusion criteria: * subject must have completed all dosing requirements in ps0016 without meeting any withdrawal criteria * female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception up till 20 weeks after last administration of study drug, and have a negative pregnancy test at visit 1 (screening) and immediately prior to first dose * male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, up till 20 weeks after the last administration of study medication (anticipated 5 half-lives) exclusion criteria: * subjects previously participating in this study * subject has any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study. note: for any subject with an ongoing serious adverse event (sae), or a history of serious infections (including herpes zoster or hospitalizations) in ps0016, the medical monitor must be consulted prior to the subject's entry into ps0018 * subject has any current sign or symptom that may indicate a medically significant infection * subject has current clinically active infection with histoplasma, coccidiodes, paracoccidioides, pneumocystis, tuberculosis (tb), nontuberculous mycobacteria (ntmb),blastomyces, aspergillus, or candidiasis (systemic). any subject diagnosed with histoplasmosis, coccidiodes, paracoccidioides, pneumocystis, tb, ntmb, blastomyces, aspergillus, or candidiasis (systemic) during ps0016 is excluded from ps0018 even if treatment has been completed. * any subject who meets any withdrawal criteria in the feeder study (ps0016) is excluded from participating in the open-label extension study (ps0018)

Keywords: psoriasis chronic plaque psoriasis bimekizumab
cognitive behavioral therapy for insomnia to address insomnia symptoms in people with multiple sclerosis

Conditions: Insomnia

Summary: the purpose of this study is to learn if cognitive behavioral therapy for insomnia (cbt-i) will improve sleep quality, fatigue, and quality of life in individuals with multiple sclerosis (ms) with symptoms of insomnia.


Eligibility criteria:
inclusion criteria: * diagnosis of ms by physician * report of difficulty falling asleep, maintaining sleep, or waking up too early at least 3 nights/week for the past 6 months, * ≥10 on insomnia severity index * english speaking * core at least 24 on the mini-mental state exam (mmse) to indicate reduced risk of dementia exclusion criteria: * known untreated sleep disorder (such as sleep apnea or restless leg syndrome) * \>4 on stop bang indicating high risk of sleep apnea * increased risk of restless leg syndrome on restless legs syndrome (rls) diagnosis index * nervous system disorder other than ms * relapse and/or corticosteroid use in past 8 weeks

Keywords: multiple sclerosis